Introduction

Upper gastrointestinal (UGI) endoscopy is a procedure that looks at the tissues lining the esophagus, stomach and the first part of the small intestine (duodenum). It uses a flexible tube-like tool called an endoscope that contains fibers that transmit light and magnify the image. The scope is inserted through the mouth and the procedure is usually performed with light, intravenous anesthesia. The scope is used to search for cause(s) of severe heartburn, difficulty swallowing, reflux, persistent vomiting, and bleeding. This tool can also be used to remove polyps or stones from the bile duct.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.
### Condition

<table>
<thead>
<tr>
<th>Medical Necessity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Malignant indications</strong></td>
</tr>
<tr>
<td>Upper gastrointestinal (UGI) endoscopy may be considered medically necessary for any of the following indications:</td>
</tr>
<tr>
<td>• Barrett esophagus (Metaplastic columnar or glandular epithelium) (see surveillance criteria below)</td>
</tr>
<tr>
<td>• Dysplasia</td>
</tr>
<tr>
<td>• Esophageal cancer</td>
</tr>
<tr>
<td>• Familial adenomatous polyposis (FAP)</td>
</tr>
<tr>
<td>• Gastric cancer</td>
</tr>
<tr>
<td>• Head/neck cancer</td>
</tr>
<tr>
<td>• History of Lynch Syndrome or hereditary nonpolyposis colorectal cancer (HNPCC)</td>
</tr>
<tr>
<td>• In situations where clinical features are highly suspicious for UGI malignancy (e.g., epigastric mass found on x-ray, abnormal barium study, and others)</td>
</tr>
<tr>
<td>• Individuals with prior adenomatous gastric polyps or sessile polyps (rare)</td>
</tr>
<tr>
<td>• One evaluation for positive CDH1 mutation</td>
</tr>
<tr>
<td>• Strong family history of gastrointestinal cancer</td>
</tr>
<tr>
<td>• Tylosis (genetic disorder which predisposes one to esophageal cancer)</td>
</tr>
</tbody>
</table>

<p>| <strong>Alarm symptoms</strong> |
| Upper gastrointestinal (UGI) endoscopy may be considered medically necessary when performed for evaluation of ANY of the following alarm symptoms that may be associated with an UGI source: |
| • Unexplained anemia or iron deficiency anemia when colonoscopy results are negative |
| • Bleeding from the rectum or in stool that may be bright red or dark colored |
| • Epigastric mass is found on examination |
| • Persistent vomiting of unknown cause, including vomiting blood |
| • Swallowing that is difficult (dysphagia) |
| • Unintentional weight loss of 3 kg (approx. 6.6 lbs.) or more since symptoms started |</p>
<table>
<thead>
<tr>
<th>Condition</th>
<th>Medical Necessity</th>
</tr>
</thead>
</table>
| Follow-up of known non-malignant conditions | Upper gastrointestinal (UGI) endoscopy may be considered medically necessary when performed for evaluation of ANY of the following indications that may be associated with a UGI source:  
  • Anorexia of unknown cause  
  • Evaluation of individuals with suspected portal hypertension or cirrhosis to document or treat esophageal varices (see Cirrhosis below for ongoing screening)  
  • Follow-up of known eosinophilic esophagitis  
  • Follow-up of known erosive esophagitis - (May need follow up UGI to evaluate for Barrett after 2-month course of therapy)  
  • For therapeutic banding (ligation) or sclerotherapy of esophageal varices, then:  
    o Repeat UGI until eradication of varices is complete, then surveillance in the following intervals:  
      ▪ One to 3 months after eradication is completed, then  
      ▪ Every 6 to 12 months thereafter to monitor for recurrence  
  • For treatment of bleeding from lesions such as ulcers (e.g., electrocoagulation, or injection therapy)  
  • History of gastric surgery  
  • Non-steroidal anti-inflammatory drug (NSAID) use is stopped yet symptoms continue (e.g., long term use for arthritis)  
  • Persistent non-cardiac chest pain  
  • Swallowing that is difficult (dysphagia)  
  • Swallowing that is painful (odynophagia) |
| Gastroesophageal reflux (GERD) or dyspepsia symptoms | Upper gastrointestinal (UGI) endoscopy may be considered medically necessary when:  
  • Performed for evaluation of GERD or dyspepsia (heartburn) symptoms that are present for at least 3 months  
  **AND**  
    o Persist despite 8 weeks of continuous treatment with daily proton pump inhibitor (PPI) therapy  
  **OR**  
    • Performed for evaluation of the return of GERD or dyspepsia (heartburn) symptoms after PPI therapy has been discontinued |
<table>
<thead>
<tr>
<th>Condition</th>
<th>Medical Necessity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other upper gastrointestinal (UGI)</td>
<td>Upper gastrointestinal (UGI) endoscopy may be considered medically necessary for any of the following indications:</td>
</tr>
<tr>
<td>indications</td>
<td>• Achalasia</td>
</tr>
<tr>
<td></td>
<td>• Barrett esophagus (BE) surveillance based on the cell pathology:</td>
</tr>
<tr>
<td></td>
<td>o High-grade dysplasia: repeat UGI every 3 months after initial biopsy for 1 year, then annually</td>
</tr>
<tr>
<td></td>
<td>o Other grades of dysplasia: repeat UGI no more frequently than annually</td>
</tr>
<tr>
<td></td>
<td>o No dysplasia (metaplasia): repeat UGI one time within 12 months after initial biopsy; then every 3 years if pathology unchanged</td>
</tr>
<tr>
<td></td>
<td>• Cirrhosis upon initial diagnosis, one UGI endoscopy to screen for esophageal varices, then no more frequently than annually for ongoing screening or surveillance</td>
</tr>
<tr>
<td></td>
<td>• Crohn disease that involves the esophagus, stomach, or duodenum</td>
</tr>
<tr>
<td></td>
<td>• Eating or drinking (ingestion) of a caustic agent</td>
</tr>
<tr>
<td></td>
<td>• Removal of a foreign body that is known or suspected</td>
</tr>
<tr>
<td></td>
<td>• Gastric, peptic, esophageal ulcer confirmation when:</td>
</tr>
<tr>
<td></td>
<td>o Conservative medical management was tried and failed to relieve symptoms (e.g., cessation of NSAIDs, trial of appropriate medication)</td>
</tr>
<tr>
<td></td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td>o Conservative medical management is contraindicated</td>
</tr>
<tr>
<td></td>
<td>• Follow-up UGI for gastric, peptic, or esophageal ulcer every 2 months until healed</td>
</tr>
<tr>
<td></td>
<td>• Individuals planned for organ transplantation where the presence of upper GI pathology might modify their management</td>
</tr>
<tr>
<td></td>
<td>• Performed for preoperative endoscopic evaluation of an individual prior to bariatric surgery (NOTE: if member’s contract excludes bariatric surgery, then UGI is not covered, unless the member meets another medical necessity criterion in this policy)</td>
</tr>
<tr>
<td></td>
<td>• Pernicious anemia symptoms (such as fatigue, shortness of breath, pale skin, red tongue, lightheadedness, and</td>
</tr>
<tr>
<td>Condition</td>
<td>Medical Necessity</td>
</tr>
<tr>
<td>-----------</td>
<td>------------------</td>
</tr>
<tr>
<td></td>
<td>numbness/tingling/pins and needles in hands and feet) when blood tests are inconclusive</td>
</tr>
<tr>
<td></td>
<td>• Post cardiac ablation for treatment of arrhythmias (irregular heart rhythms)</td>
</tr>
<tr>
<td></td>
<td>• Screening for Barrett in a male individual aged 50 years or older with 5 years or more of GERD symptoms and 1 or more of the following:</td>
</tr>
<tr>
<td></td>
<td>o Elevated body mass index (BMI)</td>
</tr>
<tr>
<td></td>
<td>o Excess abdominal fat (intra-abdominal fat distribution)</td>
</tr>
<tr>
<td></td>
<td>o Hiatal hernia</td>
</tr>
<tr>
<td></td>
<td>o Night-time symptoms of reflux</td>
</tr>
<tr>
<td></td>
<td>o Tobacco use</td>
</tr>
<tr>
<td></td>
<td>• To assess diarrhea in individuals suspected of having small-bowel disease (e.g., celiac disease) or inflammatory bowel disease</td>
</tr>
<tr>
<td></td>
<td>• UGI tract stricture or obstruction</td>
</tr>
<tr>
<td>Any other condition not addressed in this policy</td>
<td>Upper gastrointestinal (UGI) endoscopy is considered not medically necessary when criteria are not met for any of the above documented clinical indications.</td>
</tr>
</tbody>
</table>

**Upper gastrointestinal (UGI) endoscopy is considered not medically necessary when:**

- Performed for evaluation of UGI symptoms that are chronic, non-progressive, atypical for known organic disease, and are considered functional in origin (infrequent exceptions exist when a one-time endoscopic examination may be done to rule out organic disease, in cases where symptoms are unresponsive to therapy)
- Performed for evaluation of uncomplicated heartburn that responds to conservative medical management
- Performed for evaluation of UGI conditions/diagnoses when the endoscopy results will not alter management
- Performed for evaluation of x-ray findings showing any of the following:
  - Deformed duodenal bulb that is asymptomatic or has responded to ulcer therapy
### Condition | Medical Necessity
---|---
|  | o Duodenal bulb ulcer that is uncomplicated and has responded to therapy
|  | o Sliding hiatal hernia that is asymptomatic or uncomplicated
|  | • Performed as routine screening of the upper gastrointestinal (UGI) tract in the absence of a clinical indication
|  | • Performed for surveillance of healed benign disease (e.g., gastric or duodenal ulcer)
|  | • Performed for surveillance of individuals with gastric intestinal metaplasia

### Documentation Requirements

**Clinical notes for member 19 years of age or older documenting:**
- Malignant indications or alarm symptoms
- High risk known non-malignant conditions needing follow up or treatment (e.g., suspected portal hypertension or cirrhosis, eosinophilic esophagitis, erosive esophagitis, anorexia of unknown cause, esophageal varices, treatment of bleeding from lesions such as ulcers, history of gastric surgery, swallowing that is difficult or painful, etc.)
- GERD or indigestion that has lasted at least three months that continues despite trial of:
  - 8 weeks of continuous daily proton pump inhibitor (PPI) therapy
  - OR
  - GERD or indigestion symptoms that have returned after PPI has been discontinued
- Other gastrointestinal (GI) indications (e.g., achalasia, Barrett esophagus surveillance based on cell pathology, ulcer confirmation and follow-up, for preoperative endoscopic evaluation prior to bariatric surgery, to assess diarrhea in individuals suspicious of having small bowel disease (e.g., celiac disease) or IBD, etc.)

### Coding

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td></td>
</tr>
<tr>
<td>43235</td>
<td>Esophagogastroduodenoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)</td>
</tr>
<tr>
<td>43238</td>
<td>Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s), (includes endoscopic</td>
</tr>
</tbody>
</table>
### Code | Description
--- | ---
 | ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent structures
43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple
43242 | Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis)

## Related Information

### Consideration of Age

There is very little incidence and evidence of upper endoscopy in pediatrics. The age stated in the policy is for men older than 50 years with chronic GERD symptom and additional risk factors. This criterion is based on the 2012 American College of Physicians clinical guidelines for upper endoscopy.

### Definitions of Terms

**Achalasia:** An esophageal motility disorder involving the smooth muscle of the esophagus and the lower esophageal sphincter (LES).

**Barrett esophagus:** Gastroesophageal reflux disease (GERD) damages the esophageal epithelium, and the normal squamous epithelium is replaced by metaplastic columnar or glandular epithelium. This predisposes the person to esophageal adenocarcinoma.

**Crohn’s or Crohn disease:** A type of inflammatory bowel disease (IBD) that may affect any part of the gastrointestinal tract from mouth to anus. This may also be known as Crohn syndrome or regional enteritis.

**Celiac disease:** An autoimmune digestive disorder, also known as celiac sprue or gluten-sensitive enteropathy. When foods with gluten are eaten, the body’s reaction causes damage to the intestinal lining.
**Cirrhosis:** Scarring of the liver because of injury or long-term disease. The most common causes in the U.S. are chronic alcoholism and hepatitis. A small number of people with cirrhosis get liver cancer (see *esophageal varices*).

**Dyspepsia:** A chronic or recurrent pain or discomfort centered in the upper abdomen; individuals with predominant or frequent (more than once a week) heartburn or acid regurgitation (see *GERD*).

**Dysphagia:** This term applies to difficulty or inability to swallow.

**Esophagogastroduodenoscopy (EGD):** This term may be used in place of upper gastrointestinal endoscopy.

**Esophageal varices:** Abnormally enlarged veins in the lower part of the esophagus, usually formed in the presence of a clot or when scar tissue in the liver obstructs blood flow.

**Gastrointestinal:** A broad term relating to the organs and muscles of the digestive system (e.g., esophagus, stomach, small/large intestine).

**Gastroesophageal reflux disease (GERD):** A digestive disorder affecting the lower esophageal sphincter (LES) (see *dyspepsia*).

**Odynophagia:** The sensation of burning, squeezing pain when swallowing.

**Medical management:** Non-invasive interventions such as acid suppressive medications, nutritional counseling for dietary changes (to avoid foods that trigger symptoms), weight loss counseling, environmental changes (e.g., elevating the head of bed) and others.

**Serology tests:** Blood tests that look for specific antibodies in the serum of the blood. These tests are used to diagnose certain disease conditions, such as celiac disease.

**Tylosis:** A rare autosomal dominant syndrome that causes thickened skin on the palms of the hands and soles of the feet, associated with increased risk of esophageal squamous cell carcinoma.

---

**Histamine 2 Receptor Antagonists (H2RA, or H2 blockers) Use**

These medications have not been shown to heal esophagitis. A trial of standard dose H2 blockers may be used as a substitute for a trial of PPI therapy only if the member cannot tolerate
PPIs or has a contraindication to their use. Both H2RA and PPI medications treatment regimens are shown in Table 1.

Table 1. Initial Treatment of Gastroesophageal Reflux Disease

<table>
<thead>
<tr>
<th>Medication</th>
<th>Low Dose (adult, oral)</th>
<th>Standard Dose (adult, oral)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Histamine 2 Receptor Antagonists</strong>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Famotidine (Pepcid)</td>
<td>10 mg twice daily¶</td>
<td>20 mg twice dailyΔ</td>
</tr>
<tr>
<td>Nizatidine (Axid)</td>
<td>75 mg twice daily¶</td>
<td>150 mg twice daily</td>
</tr>
<tr>
<td>Cimetidine (Tagamet)</td>
<td>200 mg twice daily¶</td>
<td>400 mg twice dailyΔ</td>
</tr>
<tr>
<td><strong>Proton Pump Inhibitors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Omeprazole (Prilosec)</td>
<td>10 mg daily◊</td>
<td>20 mg daily¶</td>
</tr>
<tr>
<td>Lansoprazole (Prevacid)</td>
<td>15 mg daily¶</td>
<td>30 mg daily</td>
</tr>
<tr>
<td>Esomeprazole (Nexium)</td>
<td>10 mg daily◊</td>
<td>20 mg daily¶</td>
</tr>
<tr>
<td>Pantoprazole (Protonix)</td>
<td>20 mg daily¶</td>
<td>40 mg daily</td>
</tr>
<tr>
<td>Dexlansoprazole (Dexilant)</td>
<td>Not available</td>
<td>30 mg daily,</td>
</tr>
<tr>
<td>Rabeprazole (Aciphex)</td>
<td>10 mg daily◊</td>
<td>20 mg daily</td>
</tr>
</tbody>
</table>

GERD: gastroesophageal reflux disease; US: United States.
* Histamine 2 receptor antagonists require dose adjustment in the setting of renal insufficiency.
¶ Available without a prescription (over the counter) in the US.
Δ The daily dose for initial healing of esophagitis with erosions and symptoms of GERD in the US prescribing information is up to twice the standard dose shown in this table.
◊ Strength not available in US. Available elsewhere.
Prepared with data from:
Source: ©2022 UpToDate®

Evidence Review

In the absence of a clear cancer diagnosis, professional societies indicate that conservative medical management of gastrointestinal symptoms should be the first intervention before an invasive diagnostic test such as an upper gastrointestinal (UGI) endoscopy.¹²,¹⁷,²⁴
Description

Upper gastrointestinal (UGI) endoscopy also known as esophagogastroduodenoscopy (EGD) and gastroscopy is a procedure that examines the upper gastrointestinal tract using a flexible tube-like instrument containing light transmitting fibers that return a magnified image directly or by video. The instrument is inserted through the mouth permitting visual inspection of the esophagus, stomach and first part of the small intestine (upper duodenum). Primarily a diagnostic tool, the endoscope is used to search for cause(s) of severe heartburn (dyspepsia), difficulty swallowing (dysphagia), gastroesophageal reflux disease (GERD), persistent vomiting, and frank GI bleeding. Certain therapeutic procedures can be performed using an endoscope such as removal of polyps, papilla, and removal of stones from the bile duct. UGI endoscopy is usually performed under light sedation using an intravenous medication.

Non-cardiac Chest Pain (NCCP)

NCCP describes pain in the chest area that is similar to heart muscle pain (also called angina) in individuals who have undergone a cardiac workup and were found not to have heart disease. NCCP occurs in men and women of all ages as well as children. Because of the anatomy of the chest cavity with the heart and esophagus resting near each other, pain from either organ may be similar, which makes it hard to differentiate the pain source. Individuals who continue to have chest pain after a cardiac work up fails to provide evidence of heart disease may need a GI work up. The American College of Gastroenterology makes a strong recommendation stating that “a cardiac cause should be excluded in patients with chest pain before the commencement of a gastrointestinal evaluation”.¹

Surveillance for Barret Esophagus

Surveillance for esophageal adenocarcinoma is recommended for those diagnosed with Barrett esophagus.⁵ However, there are few data to guide recommendations about management and surveillance, and many issues are controversial. In 2015 guidelines from the American College of Gastroenterology (ACG)¹⁹ and a consensus statement from an international group of experts (Benign Barrett’s and CAncer Taskforce) on the management of Barrett esophagus were published.¹⁷ ACG recommendations for surveillance are stratified by the presence of dysplasia. When no dysplasia is detected, ACG has reported the estimated risk of progression to cancer for
individuals ranges from 0.2% to 0.5% per year and ACG has recommended endoscopic surveillance every 3 to 5 years. For low-grade dysplasia, the estimated risk of progression is about 0.7% per year, and ACG has recommended endoscopic therapy or surveillance every 12 months. For high-grade dysplasia, the estimated risk of progression is about 7% per year, and ACG has recommended endoscopic therapy. The Benign Barrett’s and CAncer Taskforce consensus group did not endorse routine surveillance for people with no dysplasia and was unable to agree on surveillance intervals for low-grade dysplasia.

Practice Guidelines and Position Statements

American College of Physicians (ACP)

In December of 2012, the American College of Physicians (ACP) published clinical guidelines for upper endoscopy for gastroesophageal reflux disease. The best practice recommendations from the professional organization follow.

Best Practice Advice 1

Upper endoscopy is indicated in men and women with heartburn and any of the following alarm symptoms:

- Anemia
- Bleeding
- Dysphagia
- Recurrent vomiting
- Weight loss

Best Practice Advice 2

Upper endoscopy is indicated in men and women with:

- Typical gastroesophageal reflux disease (GERD) symptoms that persist despite a therapeutic trial of 4 to 8 weeks of twice-daily proton-pump inhibitor therapy.
• Severe erosive esophagitis after a 2-month course of proton-pump inhibitor therapy to assess healing and rule out Barrett esophagus. Recurrent endoscopy after this follow-up examination is not indicated in the absence of Barrett esophagus.

• History of esophageal stricture that have recurrent symptoms of dysphagia

**Best Practice Advice 3**

Upper endoscopy may be indicated:

• In men older than 50 years with chronic GERD symptoms (symptoms for more than 5 years) and additional risk factors (nocturnal reflux symptoms, hiatal hernia, elevated body mass index, tobacco use, and intra-abdominal distribution of fat) to detect esophageal adenocarcinoma and Barrett esophagus.

• For surveillance evaluation in men and women with a history of Barrett esophagus. In men and women with Barrett esophagus and no dysplasia, surveillance examinations should occur at intervals no more frequently than 3 to 5 years. More frequent intervals are indicated in patients with Barrett esophagus and dysplasia.

**American College of Gastroenterology (ACG)**

In 2022, the American College of Gastroenterology (ACG) updated their 2013 guidelines for the diagnosis and management of GERD. The relevant guideline information follows:

**Establishing the Diagnosis of Gastroesophageal Reflux Disease (GERD) from the ACG Recommendations**

The diagnosis of GERD is made using some combination of symptom presentation, objective testing with endoscopy, ambulatory reflux monitoring, and response to antisecretory therapy.

1. For patients with classic GERD symptoms of heartburn and regurgitation who have no alarm symptoms an 8 week trial of empiric PPIs once daily before a meal is recommended. (Strong recommendation, moderate level of evidence.)
2. Attempting to discontinue PPIs in patients whose classic GERD symptoms respond to an 8-week empiric trial of PPIs is recommended. (Conditional recommendation, moderate level of evidence.)

3. A diagnostic endoscopy is recommended, ideally after PPIs are stopped for 2–4 weeks, in patients whose classic GERD symptoms do not respond adequately to an 8-week empiric trial of PPIs or whose symptoms return when PPIs are discontinued. (Strong recommendation, low level of evidence.)

4. In patients who have chest pain without heartburn and who have had adequate evaluation to exclude heart disease, objective testing for GERD (endoscopy and/or reflux monitoring) is recommended. (Conditional recommendation, low level of evidence.)

5. Use of a barium swallow solely as a diagnostic test for GERD is not recommended. (Conditional recommendation, low level of evidence.)

6. Endoscopy as the first test for evaluation of patients presenting with dysphagia or other alarm symptoms (weight loss and GI bleeding) and for patients with multiple risk factors for Barrett’s esophagus is recommended. (Strong recommendation, low level of evidence.)

7. In patients for whom the diagnosis of GERD is suspected but not clear, and endoscopy shows no objective evidence of GERD, reflux monitoring is recommended to be performed off therapy to establish the diagnosis. (Strong recommendation, low level evidence.)

8. Reflux monitoring off therapy solely as a diagnostic test for GERD in patients known to have endoscopic evidence of Los Angeles (LA) grade C or D reflux esophagitis or in patients with long-segment Barrett’s esophagus is not recommended. (Strong recommendation, low level of evidence.)

### Table 2. Diagnostic Testing for GERD and Utility of Tests

<table>
<thead>
<tr>
<th>Diagnostic Test</th>
<th>Indication</th>
<th>Highest Level of Evidence</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPI trial</td>
<td>Classic symptoms, no warning signs.</td>
<td>Meta-analysis</td>
<td>Negative trial does not rule out GERD.</td>
</tr>
<tr>
<td>Barium swallow</td>
<td>Not for GERD diagnosis. Use of evaluation of dysphagia.</td>
<td>Case-control</td>
<td>Do not use unless evaluating for complication (stricture, ring).</td>
</tr>
<tr>
<td>Diagnostic Test</td>
<td>Indication</td>
<td>Highest Level of Evidence</td>
<td>Recommendation</td>
</tr>
<tr>
<td>-------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>---------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Endoscopy</td>
<td>Alarm symptoms, screening of high-risk patients, chest pain.</td>
<td>Randomized control trial</td>
<td>Consider early for elderly, those at risk for Barrett’s, non-cardiac chest pain, patients unresponsive to PPI</td>
</tr>
<tr>
<td>Esophageal biopsy</td>
<td>Exclude non-GERD causes for symptoms.</td>
<td>Case-Control</td>
<td>Not indicated for diagnosis of GERD.</td>
</tr>
<tr>
<td>Ambulatory reflux</td>
<td>Preoperatively for non-erosive disease. Refractory GERD symptoms, GERD</td>
<td>Observational</td>
<td>Correlate symptoms with reflux, document abnormal acid exposure or reflux frequency.</td>
</tr>
<tr>
<td></td>
<td>diagnosis in question.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GERD=gastroesophageal reflux disease; PPI=proton pump inhibitor

**American Society for Gastrointestinal Endoscopy (ASGE)**

In 2012, the ASGE⁶ published guidelines for standards of practice (SOP) recommendations for the appropriate use of esophagogastroduodenoscopy (EGD) with the following indications.

Esophagogastroduodenoscopy is generally indicated for evaluating:

A. Upper abdominal symptoms that persist despite an appropriate trial of therapy

B. Upper abdominal symptoms associated with other symptoms or signs suggesting serious organic disease (e.g., anorexia and weight loss) or in patients aged > 45 years

C. Dysphagia or odynophagia

D. Esophageal reflux symptoms, which are persistent or recurrent despite appropriate therapy

E. Persistent vomiting of unknown cause

F. Other diseases in which the presence of upper GI pathology might modify other planned management. Examples include patients who have a history of ulcer or GI bleeding who are scheduled for organ transplantation, long-term anti-coagulation, or chronic non-steroidal anti-inflammatory drug therapy for arthritis, and those with cancer of the head and neck.
G. Familial adenomatous polyposis syndromes

H. For confirmation and specific histological diagnosis of radiologically demonstrated lesions:
   1. Suspected neoplastic lesion
   2. Gastric or esophageal ulcer
   3. Upper tract stricture or obstruction

I. Gastrointestinal bleeding:
   1. In patients with active or recent bleeding
   2. For presumed chronic blood loss and for iron deficiency anemia when the clinical situation suggests an upper GI source or when colonoscopy is negative

J. When sampling of tissue or fluid is indicated

K. In patients with suspected portal hypertension to document or treat esophageal varices

L. To assess acute injury after caustic ingestion

M. Treatment of bleeding lesions such as ulcers, tumors, vascular abnormalities (e.g., electrocoagulation, heater probe, laser photocoagulation or injection therapy)

N. Banding or sclerotherapy of varices

O. Removal of foreign bodies

P. Removal of selected polypoid lesions

Q. Placement of feeding or drainage tubes (peroral, percutaneous endoscopic gastrostomy PEG), percutaneous endoscopic jejunostomy

R. Dilation of stenotic lesions (e.g., with transendoscopic balloon dilators or dilation systems by using guide wires)

S. Management of achalasia (e.g., botulinum toxin, balloon dilation)

T. Palliative treatment of stenosing neoplasms (e.g., laser, multi-polar electrocoagulation, stent placement)

U. Endoscopic therapy of intestinal metaplasia
V. Intraoperative evaluation of anatomic reconstructions typical of modern foregut surgery (e.g., evaluation of anastomotic leak and patency, fundoplication formation, pouch configuration during bariatric surgery)

W. Management of operative adverse events (e.g., dilation of anastomotic strictures, stenting of anastomotic disruption, fistula, or leak in selected circumstances)

Esophagogastroduodenoscopy is generally not indicated for evaluating:

A. Symptoms that are considered functional in origin (there are exceptions in which an endoscopic examination may be done once to rule out organic disease, especially if symptoms are unresponsive to therapy)

B. Metastatic adenocarcinoma of unknown primary site when the results will not alter management

C. Radiographic findings of:
   1. Asymptomatic or uncomplicated sliding hiatal hernia
   2. Uncomplicated duodenal ulcer that has responded to therapy
   3. Deformed duodenal bulb when symptoms are absent or respond adequately to ulcer therapy

Sequential or periodic EGD may be indicated:

A. Surveillance for malignancy in patients with pre-malignant conditions (e.g. Barrett’s esophagus)

Sequential or periodic EGD is generally not indicated for:

A. Surveillance for malignancy in patients with gastric atrophy, pernicious anemia, or fundic gland or hyperplastic polyps, gastric intestinal metaplasia, or prior gastric operations for benign disease

B. Surveillance of healed benign disease such as esophagitis or gastric or duodenal ulcer

C. Surveillance during repeated dilation of benign strictures unless there is a change in status
Medicare National Coverage

The coverage statement is that “Endoscopic procedures are covered when reasonable and necessary for the individual patient.”

References


28631728. Available online at:


## History

<table>
<thead>
<tr>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/10/13</td>
<td>New policy. Add to Utilization Management section. Policy approved with 90-day hold for provider notification. The policy effective date is October 1, 2013.</td>
</tr>
<tr>
<td>08/15/13</td>
<td>Update Related Policies. Remove 2.01.520 and add 2.01.20.</td>
</tr>
<tr>
<td>09/05/13</td>
<td>Coding update. CPT code 43252 removed from policy as it pertains to another policy (2.01.87).</td>
</tr>
<tr>
<td>08/11/14</td>
<td>Annual Review. Changed the title to Upper Gastrointestinal (UGI) Endoscopy for Adults, for ease of finding the document. Policy extensively re-written. Policy statements reorganized but intent is unchanged. Revised “adult” to patients of 19 years old and older. Policy updated with literature search through June, 2014. Reference to using MCG as a tool to guide determinations is removed. References 6-10 added; others renumbered/removed. New CPT codes 43233, 43253, 43254, 43266, 43270 added for 2014. Policy statements changed as noted.</td>
</tr>
<tr>
<td>10/13/14</td>
<td>Interim Update. Removed Policy statement under UGI Tract Symptoms header that states “interferes with activities of daily living on 3 or more days a week”. Extensive editorial changes to consolidate and simplify criteria in the policy statements. Clarification for non-cardiac chest pain (NCCP) added to the rationale section. Reference 5 added; others renumbered. Policy statements revised, intent is unchanged.</td>
</tr>
<tr>
<td>12/22/14</td>
<td>Interim Update. Policy reclassified, renumbered from 11.01.504 to 2.01.533 and moved from UM section to Medicine section. Reference 1 removed; others renumbered and broken hyperlinks repaired. Policy statements unchanged.</td>
</tr>
<tr>
<td>05/12/15</td>
<td>Annual Review. Policy updated with literature search through April, 2015. Added esophageal varices with or without bleeding to the Follow Up of Known Conditions list. Added new cirrhosis diagnosis to the Other Indications list. Cirrhosis added to Definition of Terms. Added AASLD recommendations to Practice Guidelines and Position Statements section. References 10,13 added; others renumbered. Policy statements changed as noted. Remove informational CPT codes: 43233-34, 43237, 43263, 43270.</td>
</tr>
<tr>
<td>Date</td>
<td>Comments</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>43240-41, 43243-43256; 43258-59; 43270; remove ICD-9 diagnosis codes, as they do not affect policy adjudication.</td>
<td>06/02/15 Update Related Policies. Remove 2.01.81 as it was archived.</td>
</tr>
<tr>
<td>02/09/16</td>
<td>Annual Review. No change in coverage statements. Removed reference 6, Medicare LCD no longer available.</td>
</tr>
<tr>
<td>08/01/16</td>
<td>Interim Review, approved July 12, 2016. Added information on histamine 2 receptor antagonists and table to Related Information section; reference 13 added. Policy moved into new format; no change to policy statements.</td>
</tr>
<tr>
<td>01/01/17</td>
<td>Interim Review, approved December 13, 2016. Clarified the description for bleeding in the Alarm Symptoms and GI bleeding sections of the policy. Changed “gastric bypass surgery” to “bariatric surgery” under the section listing Other Upper Gastrointestinal (UGI) Indications.</td>
</tr>
<tr>
<td>02/03/17</td>
<td>Minor update. Replaced the acronym “EGD” with “UGI” within policy section for purposes of consistency. No other changes; policy statements remain the same.</td>
</tr>
<tr>
<td>01/01/18</td>
<td>Annual Review, approved December 12, 2017. Modified criteria to include surveillance for individuals with cirrhosis. Clarified UGI not covered for bariatric surgery when bariatric surgery is contractually excluded, unless other symptoms are present. Completely reorganized policy criteria. No references added. Removed CPT code 43236.</td>
</tr>
<tr>
<td>03/09/18</td>
<td>Minor edit; added Documentation Requirements section.</td>
</tr>
<tr>
<td>09/01/18</td>
<td>Interim Review, approved August 10, 2018. Minor edit; added surveillance criteria for Barrett’s esophagus no dysplasia (metaplasia). Re-added Consideration of Age information, which was inadvertently removed during a previous update.</td>
</tr>
<tr>
<td>12/01/18</td>
<td>Annual Review, approved November 6, 2018. Minor editing and formatting for clarity. References 13-14 added. No change to policy statements.</td>
</tr>
<tr>
<td>01/01/19</td>
<td>Interim Review, approved December 19, 2018. Reference 15 added. Added positive CDH1 mutation indication.</td>
</tr>
<tr>
<td>12/01/19</td>
<td>Interim Review, approved November 26, 2019. This policy effective date was updated to January 1, 2020.</td>
</tr>
<tr>
<td>04/01/20</td>
<td>Delete policy, approved March 10, 2020. This policy will be deleted effective July 2, 2020, replaced with policy 10.01.530.</td>
</tr>
<tr>
<td>07/02/20</td>
<td>Delete policy.</td>
</tr>
<tr>
<td>Date</td>
<td>Comments</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>06/01/21</td>
<td>Criteria clarification; added two-month course of therapy under criteria for follow-up of known erosive esophagitis.</td>
</tr>
<tr>
<td>06/01/22</td>
<td>Annual Review, approved May 10, 2022. Policy reviewed. References updated. Reference added. Modified UGI medically necessary policy statement for GERD or dyspepsia symptoms to now state persists despite 8 weeks of continuous daily PPI therapy OR performed for evaluation of GERD or dyspepsia symptoms that have returned after PPI therapy has been discontinued. Deleted statement on H2 blocker therapy. Added medically necessary statement for follow-up of known eosinophilic esophagitis. Changes are effective for dates of service on or after September 2, 2022.</td>
</tr>
<tr>
<td>09/01/22</td>
<td>Interim Review, approved August 9, 2022. Added therapeutic banding (ligation) or sclerotherapy of esophageal varices as medically necessary.</td>
</tr>
<tr>
<td>01/01/23</td>
<td>Interim Review, approved December 13, 2022. References added. Preoperative UGI prior to bariatric surgery was changed from not medically necessary to medically necessary. Clarifications made to surveillance schedule for esophageal varices. Added UGI is medically necessary to assess diarrhea in individuals suspicious of having small bowel disease (e.g., celiac disease) or IBD. Removed the former policy criteria on celiac disease. Added UGI for treatment of bleeding lesions such as ulcers (e.g., electrocoagulation, injection therapy) is medically necessary. Added follow-up UGI for gastric, peptic, or esophageal ulcer every 2 months until healed is medically necessary. Added UGI performed for surveillance of healed benign disease (e.g., gastric or duodenal ulcer) is considered not medically necessary. Other minor edits made to policy statements, but intent of the statements was unchanged. Changed the wording from “patient” to “individual” throughout the policy for standardization.</td>
</tr>
<tr>
<td>02/01/23</td>
<td>Interim Review, approved January 10, 2023. References added. Added UGI when performed for surveillance of individuals with gastric intestinal metaplasia is considered not medically necessary. Other minor edits made for clarity only; intent of the policy statements is unchanged.</td>
</tr>
</tbody>
</table>

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2023 Premera All Rights Reserved.
**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.
Discrimination is Against the Law

Premera Blue Cross (Premera) complies with applicable Federal and Washington state civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. Premera provides free aids and services to people with disabilities to communicate effectively with us, such as qualified sign language interpreters and written information in other formats (large print, audio, accessible electronic formats, other formats). Premera provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, contact the Civil Rights Coordinator. If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation, you can file a grievance with: Civil Rights Coordinator — Complaints and Appeals, PO Box 91102, Seattle, WA 98111, Toll free: 855-332-4535, Fax: 425-918-5592, TTY: 711, Email AppealsDepartmentInquiries@Premera.com. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Ave SW, Room 500F, HHH Building, Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD). Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html.


Alaska residents: Contact the Alaska Division of Insurance via email at insurance@alaska.gov, or by phone at 907-269-7900 or 1-800-INSURAK (in-state, outside Anchorage).

Language Assistance

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 800-722-1471 (TTY: 711).


주: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 800-722-1471 (TTY: 711) 번으로 전화해 주십시오.

注意事項：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 800-722-1471 (TTY: 711)。

NOTE: For persons who cannot read or write English, free informational services are available in Commonwealth languages. Call 800-722-1471 (TTY: 711) 至 TRUE.


VARA: If you speak Vietnamese, you are entitled to free interpretation services. Call 800-722-1471 (TTY: 711).

Languages: If you speak Chinese, you are entitled to free interpretation services. Call 800-722-1471 (TTY: 711).

E-mail: If you speak Chinese, you are entitled to free interpretation services. Call 800-722-1471 (TTY: 711).

Language: If you speak Chinese, you are entitled to free interpretation services. Call 800-722-1471 (TTY: 711).

TOWAY: 어려운 중급에서 고급까지의 언어 지원 서비스를 이용하기 위하여 800-722-1471 (TTY: 711)에 전화해 주십시오.


ATTENTION: Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 800-722-1471 (ATS: 711).


Premera Blue Cross is an independent licensee of the Blue Cross Blue Shield Association serving businesses and residents of Alaska and Washington State, excluding Clark County.

052493 (07-01-2021)